Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23055854 | 0.85 | NR1H2 (0.32) | NR1H2NR1H3ATAD2ANPEP | |
| SCHEMBL23055515 | 0.84 | DDB1 (0.39) | DDB1CRBN | |
| SCHEMBL23056008 | 0.83 | NR1H2 (0.34) | NR1H2NR1H3ATAD2ANPEPLMNA | |
| SCHEMBL23055541 | 0.82 | CASP6 (0.41) | NR1H2NR1H3LMNADDB1CRBN | |
| SCHEMBL23055997 | 0.81 | NR1H2 (0.33) | NR1H2NR1H3ANPEP | |
| SCHEMBL23055495 | 0.80 | — | — | |
| SCHEMBL23055605 | 0.79 | MAPT (0.40) | LMNAHSD17B10 | |
| SCHEMBL23055880 | 0.75 | NR1H2 (0.34) | NR1H2NR1H3ATAD2ANPEPLMNA | |
| SCHEMBL23055575 | 0.74 | GAA (0.35) | NR1H2NR1H3ATAD2ANPEPLMNA | |
| SCHEMBL23055646 | 0.70 | CRBN (0.34) | LMNAHSD17B10DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20210061761-A1 | MODULATORS OF COMPLEX I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061761-A1 | MODULATORS OF COMPLEX I | NDUFAB1, NDUFV1, NDUFB7 | NR1H2 385/4885NR1H3 685/4885ATAD2 747/4885 |
| US-11795147-B2 | Modulators of complex I | NDUFAB1, NDUFV1, NDUFB7 | NR1H2 385/4885NR1H3 685/4885ATAD2 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.